Related Experiment Video
Updated: Aug 24, 2025
07:28
Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
3.9K
Development and clinical validation of CT-based regional modified Centiloid method for amyloid PET
Soo-Jong Kim1,2,3,4, Hongki Ham1,2,4,5, Yu Hyun Park1,2,3,4
1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.
Alzheimer'S Research & Therapy
|October 21, 2022
Summary
A new CT-based method harmonizes amyloid PET imaging for Alzheimer's disease research. This approach allows regional quantification of amyloid beta (Aβ) using 18F-florbetaben (FBB) and 18F-flutemetamol (FMM) without MRI scans.
Area of Science:
- Neuroimaging
- Molecular Imaging
- Alzheimer's Disease Research
Background:
- Standard Centiloid (CL) method uses MRI for global amyloid PET quantification.
- Need exists for harmonizing regional amyloid-beta (Aβ) PET ligand quantification using CT.
- This study introduces a CT-based regional direct comparison (rdcCL) for 18F-florbetaben (FBB) and 18F-flutemetamol (FMM).
Purpose of the Study:
- To develop and validate a CT-based method for regional direct comparison of FBB and FMM Centiloid (rdcCL) values.
- To establish a common target region and regional volumes of interest (VOIs) using both MRI and CT.
- To compare global and regional rdcCL scales between MRI-based and CT-based methods.
Main Methods:
- Developed MRI-based and CT-based rdcCLs using a cohort of 63 subjects (controls and Alzheimer's disease dementia patients).
- Defined common target regions and six regional VOIs (frontal, temporal, parietal, posterior cingulate, occipital, striatal).
- Validated the CT-based rdcCL method in a larger cohort of 2245 subjects (cognitively normal, MCI, and ADD).
Main Results:
- Both MRI- and CT-based rdcCL scales showed high correlations between FMM and FBB globally and regionally (R2 = 0.96–0.99).
- CT-based rdcCL scales demonstrated high correlation with MRI-based scales for both FMM and FBB (R2 = 0.97–0.99).
- No significant differences were found in the absolute rdcCLs between CT-based and MRI-based methods, globally or regionally (p = 0.07–0.95).
- Clinical validation showed regional Aβ positivity correlated with worse neuropsychological performance.
Conclusions:
- CT-based rdcCL is a feasible method for converting regional FMM or FBB standardized uptake value ratios (rdcSUVR) into rdcCL scales.
- This CT-based approach eliminates the need for additional MRI scans, increasing accessibility.
- The method is applicable to various research conditions for harmonized regional Aβ quantification.
